Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling

por Nelson, Katelyn N., Meyer, April N., Wang, Clark G., Donoghue, Daniel J.
Publicado 2018

Oncogenic fusion protein FGFR2-PPHLN1: Requirements for biological activation, and efficacy of inhibitors

por Li, Fangda, Meyer, April N., Peiris, Malalage N., Nelson, Katelyn N., Donoghue, Daniel J.
Publicado 2020

Oncogenic driver FGFR3-TACC3 requires five coiled-coil heptads for activation and disulfide bond formation for stability

por Wang, Clark G., Peiris, Malalage N., Meyer, April N., Nelson, Katelyn N., Donoghue, Daniel J.
Publicado 2023

Novel Lys63-linked ubiquitination of IKKβ induces STAT3 signaling

por Gallo, Leandro H, Meyer, April N, Motamedchaboki, Khatereh, Nelson, Katelyn N, Haas, Martin, Donoghue, Daniel J
Publicado 2014

Oncogenic fusion protein BCR-FGFR1 requires the breakpoint cluster region-mediated oligomerization and chaperonin Hsp90 for activation

por Peiris, Malalage N., Meyer, April N., Nelson, Katelyn N., Bisom-Rapp, Ezra W., Donoghue, Daniel J.
Publicado 2020

Oncogenic mutations in IKKβ function through global changes induced by K63-linked ubiquitination and result in autocrine stimulation

por Meyer, April N., Gallo, Leandro H., Ko, Juyeon, Cardenas, Guillermo, Nelson, Katelyn N., Siari, Asma, Campos, Alexandre R., Whisenant, Thomas C., Donoghue, Daniel J.
Publicado 2018